Drugs · Entity Annotation Prototype (beta)

7articles mentioning drugs

32drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: 5-ASA ×

5-ASA

This drug is selected. Its supporting articles are shown below.

5-ASA7

Articles mentioning 5-ASA

7 articles · page 1 of 1

IDDF2026-ABS-0182 ST1A1 attenuates 5-aminosalicylic acid uptake and promotes its metabolism in intestinal epithelial cells through EGFR-MAPK signaling in ulcerative colitis

gutjnl · abstract · 2026-06-26 · 12 matching annotations

97.2%

5-ASA 5-Aminosalicylic acid 5-ASA-ineffective dextran sulfate sodium ulcerative colitis UC

…ase family 1A member 1 (ST1A1, gene name SULT1A1) in modulating 5-ASA therapeutic efficacy.Methods Baseline serum from 36 UC patients…

P185 Impact of concomitant 5-aminosalicyclic acid therapy on upadacitinib efficacy and safety in ulcerative colitis: phase 3 clinical trials post-hoc analyses

gutjnl · abstract · 2026-06-23 · 8 matching annotations

89.1%

Upadacitinib UPA45 UPA30 5-ASA UPA15 UPA

…Introduction Upadacitinib (UPA) is an oral, selective, reversible janus kinase (JAK) 1 in…

Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome – a study protocol

bmjopen · abstract · 2025-11-09 · 6 matching annotations

91.4%

Mesalamine 5-ASA ulcerative colitis CRC Lynch syndrome colorectal cancer Swedish Research Council European Clinical Trials Information System LS colorectal neoplasia+1 more

…f colorectal cancer (CRC) due to mismatch repair gene variants. Mesalamine (5-ASA, 5-aminosalicylic acid), used safely in patients with ul…

OC42 Granulomatous interstitial nephritis in paediatric Crohn’s disease. A case report

flgastro · abstract · 2026-06-29 · 2 matching annotations

92.1%

mesalamine 5-ASA ulcerative colitis Crohn’s disease tubulointerstitial nephritis amyloidosis nephrolithiasis glomerulonephritis Granulomatous interstitial nephritis IBDU

…remission and mucosal healing by September 2024, at which point mesalamine was discontinued. Concomitantly, at diagnosis, blood tests show…

IDDF2026-ABS-0209 Atractylodes macrocephala-derived carbon dot nanozymes for the multi-targeted treatment of ulcerative colitis: integrating antioxidant, anti-inflammatory, and gut barrier-protective effects

gutjnl · abstract · 2026-06-26 · 2 matching annotations

89.0%

5-ASA AM-CDs ulcerative colitis UC

…n protein expression, showing superior efficacy to conventional 5-ASA therapy (IDDF2026-ABS-0209 Figure 4. Evaluation of AM-CD effica…

OC85 Acute drug hypersensitivity reactions to infliximab in paediatric IBD patients: a single centre experience

flgastro · abstract · 2026-06-29 · 1 matching annotations

88.2%

infliximab methotrexate adalimumab azathioprine hydrocortisone allopurinol IFX Infliximab-related 5-ASA

… M, Green Z, Morris K. OC4 Discontinuation of premedication for infliximab infusions is well-tolerated, without adverse events, and cost-s…

P48 Long-term outcomes in children and young people with combined inflammatory bowel disease and hepatobiliary disease: a dual-centre experience

gutjnl · abstract · 2025-10-06 · 1 matching annotations

94.3%

prednisolone Azathioprine mycophenolate mofetil 5-ASA JAK-inhibitors colorectal cancer Primary Sclerosing Cholangitis Autoimmune Sclerosing Cholangitis gallbladder cancer ulcerative colitis+2 more

…patient with IBD-U/PSC. IBD/AIH/AISC subtypes were treated with prednisolone (61.5%), azathioprine (76.9%) or mycophenolate mofetil (15.4%).…